About US
Contact us
-
Pfizer partner CStone explores sale as US path blocked, Chinese competition heats up: BloombergA Pfizer cancer drug partner in China is considering a sale as the biotech’s commercial path in the U.S. looks uncertain and competition in its home country intensifies. CStone Pharmaceut2022/8/18
-
AstraZeneca, Pfizer, Novartis and more lose out in China's latest round of drug price cutsIn another abysmal day for large pharma companies’ off-patent drugs, generics makers have once again offered hefty discounts to win large tender offers in China, elbowing out original developers.2022/8/16
-
Pfizer partner CStone explores sale as US path blocked, Chinese competition heats up: BloombergA Pfizer cancer drug partner in China is considering a sale as the biotech’s commercial path in the U.S. looks uncertain and competition in its home country intensifies. CStone Pharmaceut2022/8/16
-
WuXi unveils new production capabilities at Changzhou campus amid expansion pushWuXi STA, a part of WuXi AppTec,unveilednew large-scale oligonucleotide and peptide manufacturing capabilities at its Changzhou production campus. The 30,570-square-foot oligonucleotide f2022/8/11
-
BeiGene R&D chief's I-O ambitions; Legend scraps CAR-T programBeiGene's R&D chief talked to Fierce Biotech about the company's PD-1 plans and how its TIGITplans are still alive despite Roche's recent trial failures. Expanding on novel technologies, BeiGenea2022/8/11
-
Athenex unloads stake in Chinese API production business for $19M to bolster its financialsStruggling biotech Athenexunloadedall of its equity interests in its Chinese subsidiaries that produce APIs as part of a $19 million deal with TiHe Capital of Beijing. Under terms of the2022/8/9
-
AstraZeneca, Pfizer, Novartis and more lose out in China's latest round of drug price cutsIn another abysmal day for large pharma companies’ off-patent drugs, generics makers have once again offered hefty discounts to win large tender offers in China, elbowing out original developers.2022/8/9
-
Eying Pfizer, Alnylam's high-stakes Onpattro heart trial delivers partial win but misses on key outcomes goalAfter an investigational BridgeBio drug surprisingly failed a clinical trial that would have set up a fight against Pfizer in a rare heart condition, investors have been worrying about Alnylam becaus2022/8/4
-
Teva runs into Adderall supply hitch as ADHD diagnoses mount, pledges prompt restockingAmid a national spike in attention-deficit/hyperactivity disorder diagnoses, one of the U.S.’ top providers of a popular ADHD medication has run into supply problems. Both 20-mg and 30-mg2022/8/4
-
Amgen partners with Fosun to bring Otezla, Parsabiv to patients in ChinaIn an effort to grow its presence in China, U.S. biotech giant Amgen has partnered with China’s Fosun Pharma to bring Otezla and Parsabiv to patients in the country. Amgen China will out-2022/8/1